#Perturb2026
LightNews LightNews
mylliabio.bsky.social
🗓️ @mylliabio.bsky.social sponsors the first conference on "High-Content CRISPR Screening" from March 18-19, 2026 in Vienna: perturb2026.bio

Scientific topics:
🔬 CRISPR-based screening strategies
🧬 Perturb-Seq & CROP-Seq
💻 Computational analyses
💻 AI models of human cells
📸 Image-based screens
August 7, 2025 at 11:46 AM
mylliabio.bsky.social
The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio
Abstract submission: perturb2026.bio/abstract-sub...

Meet the Speaker: @xinjin.bsky.social
Dr. Xin Jin is an HHMI Freeman Hrabowski Scholar, Associate Professor of Neuroscience at Scripps Research, a member of the Dorris Neuroscience Center, and Adjunct Professor of Cognitive Science at UC San Diego. She received her BSc in Chemistry from MIT and her PhD in Biology from The Rockefeller University working in the Lab of Cori Bargmann. As a Junior Fellow at the Harvard Society of Fellows, she worked with Paola Arlotta, Feng Zhang and Aviv Regev to develop and apply in vivo genetic screening technologies to study brain development and homeostasis. She is the recipient of the Pew Biomedical Scholar, McKnight Scholar Award, Early Career Investigator Award from the International Society of Autism Research and was named as one of the ‘35 Innovators Under 35’ by MIT Tech Review.
October 15, 2025 at 10:55 AM
mylliabio.bsky.social
🚀 Are you ready to push the boundaries of bio AI foundation models? @mylliabio.bsky.social is thrilled to host "Echoes of Silenced Genes" - A Global Community Prediction Competition!

🔗 Learn more here and join the competition:
myllia.com/events/commu...

#AI #BioAI #CRISPR #Perturb2026
Myllia's Perturbation Prediction Challenge 2026: Echoes of Silenced Genes - Can you predict how CRISPRi perturbations influence the phenotypes of human cells?
February 4, 2026 at 10:58 AM
mfarlik.bsky.social
Exciting to listen to a great line-up of speakers in the #Perturb2026 conference in Vienna!
Perturb Logo
March 18, 2026 at 1:01 PM
mylliabio.bsky.social
The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio

Meet the Speaker: @leopoldparts.bsky.social
Dr. Leopold Parts initially trained in mathematics and computer science before switching to molecular biology and genomics for his Ph.D., and high-throughput screening for the postdoctoral research. He is currently a group leader at the Wellcome Sanger Institute, where his team aims to understand human DNA function in its cellular context. To do so, they currently focus on generating data from cell lines whose genomes carry many large-scale systematic changes compared to the reference. His team has created several tools and datasets to probe the editing efficacies of CRISPR/Cas systems, as well as applied them to map the extent of variation in gene phenotypes between individuals.
October 29, 2025 at 8:36 AM
mylliabio.bsky.social
The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
perturb2026.bio

Meet the Speaker: Mathew Garnett

@mgarnett.bsky.social
Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.
September 29, 2025 at 12:32 PM
mylliabio.bsky.social
Are you interested in single-cell genomics and drug target discovery? The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria.

Conference website: perturb2026.bio

Meet the Speaker: @thijnbrummel.bsky.social
Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.
November 24, 2025 at 11:06 AM
mylliabio.bsky.social
Are you interested in single-cell genomics, AI-ready perturbation data and virtual cell models? The registration for the "High-Content CRISPR Screening" conference in March 2026 is open via the website:

perturb2026.bio

Meet the Speaker: Ci Chu
Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.
December 2, 2025 at 9:13 AM
mylliabio.bsky.social
High-Content CRISPR Screening Conference

March 18-19, 2026 | Vienna, Austria

Abstract submission is now open! Don’t miss the chance to hear from an outstanding line-up of speakers and connect with leading researchers in the field.

Register now: perturb2026.bio
Abstract submissions are now open for the conference on "High-Content CRISPR Screening", taking place in Vienna this March 2026. We invite researchers from across the globe to share their latest work and join the discussion shaping the future of CRISPR screening and genome editing. Scientific themes include * CRISPR-based screening strategies * Perturb-seq and CROP-seq methods * Computational analysis and data interpretation * AI models of human cells * Imaging-based CRISPR screens Date: March 18 & 19, 2026 Location: Vienna, Austria
September 19, 2025 at 9:10 AM
mylliabio.bsky.social
We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the website:
perturb2026.bio

Meet the Speaker: Jake P. Taylor-King
Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.
September 23, 2025 at 10:52 AM
mylliabio.bsky.social
We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration and abstract submission is now open via the conference website: perturb2026.bio

Meet the Speaker: @priscaliberali.bsky.social
Dr. Prisca Liberali is Full Professor at ETH Zurich (D-BSSE) and Senior Group Leader at the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel. Her laboratory combines high-content imaging, CRISPR-based perturbations, and computational modeling to uncover how single-cell variability drives tissue self-organization and regeneration. By developing quantitative pipelines that integrate genome editing with multiscale microscopy, her group maps genetic interactions and mechanochemical pathways controlling organoid morphogenesis. Liberali’s work bridges molecular systems biology, developmental dynamics, and quantitative imaging, providing mechanistic insights into how collective behaviors emerge from single-cell decisions.
November 17, 2025 at 10:16 AM
mylliabio.bsky.social
The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio

Meet the Speaker: Thomas Norman
Dr. Thomas Norman is an Assistant Member in the Computational & Systems Biology Program at Memorial Sloan Kettering, where his lab develops and applies Perturb-seq to study and engineer cell state. He co-developed Perturb-seq and has helped expand it into a platform for large-scale functional genomics, including genome-scale screens of all expressed genes, systematic CRISPRa of all human transcription factors, and the development of Multiome Perturb-seq to jointly profile gene expression and chromatin accessibility following perturbation. His lab focuses on fibroblasts as a model of cellular plasticity, with broader goals of understanding how transcriptionally-defined fibroblast subsets are specified, contribute to disease, and can be reprogrammed for therapeutic purposes.
October 29, 2025 at 8:33 AM
mylliabio.bsky.social
Are you interested in single-cell genomics and AI/ML models? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

Conference website: perturb2026.bio

Meet the Speaker: @yusufroohani.bsky.social
Dr. Yusuf Roohani is a Machine Learning Group Leader at the Arc Institute. His research explores how artificial intelligence can guide experimental design in biological discovery, with a particular focus on predictive models of cell state. Recently, he helped design the Virtual Cell Challenge, an initiative to measure progress toward predicting cell behavior under perturbation. Yusuf earned his Ph.D. at Stanford University, where he was advised by Jure Leskovec and Stephen Quake. Prior to that, he spent four years at GSK as a Machine Learning Engineer working on early-stage drug discovery.
November 6, 2025 at 11:46 AM
steglelab.bsky.social
Two weeks ago, MAIGE group leader @brianfclarke.bsky.social and Katharina, together with Dominik (Steinmetz lab) joined #Perturb2026, exploring new technologies and datasets. Highlight: Katharina’s first short talk on large-scale perturbation screens in cardioids and great discussions at our poster!
April 1, 2026 at 2:42 PM
elembio.bsky.social
We are thrilled to see Myllia Biotechnology demonstrate high-quality optical pooled screening (OPS) data on the AVITI24™! The Myllia team will be showcasing a spotlight on this important use case at #Perturb2026 this week in Vienna.

https://bit.ly/3NIhToU

#AVITI24 #Multiomics
March 17, 2026 at 3:20 PM